加载中
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
常规交易时段
US$10.565
+US$0.075 · +0.71%
盘中时间采用ET。市场数据可能有所延迟。
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
日内区间
当前US$10.565
52周区间
当前US$10.565
盘中时间采用ET。市场数据可能有所延迟。
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
日内区间
当前US$10.565
52周区间
当前US$10.565
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 639.2万 USD | 227.1万 USD | — | — | — |
| 销货成本 | 428万 USD | — | — | — | — |
| 毛利 | 211.2万 USD | 227.1万 USD | — | — | — |
| 研究与开发 | 6557.5万 USD | 6363.6万 USD | 5725万 USD | 4220.1万 USD | 2380.5万 USD |
| 销售、一般及管理费用 | 2815.9万 USD | 3054.5万 USD | 3653.6万 USD | 1679.7万 USD | 1168.9万 USD |
| 营业费用 | 8945.4万 USD | 9418.1万 USD | 8453.4万 USD | 5899.8万 USD | 3549.4万 USD |
| 利息收入 | — | — | — | 94.7万 USD | — |
| 利息支出 | — | — | — | 11.8万 USD | — |
| 折旧和摊销 | 428万 USD | 356.5万 USD | 363万 USD | 251.1万 USD | 159.5万 USD |
| 营业利润 | −8734.2万 USD | −9191万 USD | −8453.4万 USD | −5899.8万 USD | −3549.4万 USD |
| 净利润 | −1.17亿 USD | −8358.1万 USD | −8117.2万 USD | −5803.2万 USD | −2195.9万 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.00
上涨空间 41.98%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年11月6日 | 1:50 | — | — |
已生效 2023年11月6日
1:50
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM307.01万0.00%785.63亿 USD0.19%US$277.33-0.14%
Vanguard Morningstar Total Stock Market ETFVTI244.48万0.00%2.3万亿 USD0.03%US$378.7-0.61%
Vanguard Extended Market ETFVXF87.95万0.00%954亿 USD0.05%US$232.74-0.32%
Vanguard Russell 2000 ETFVTWO79.99万0.00%180亿 USD0.06%US$112.01-0.18%
F/M Emerald Life Sciences Innovation ETFLFSC67.6万0.59%1.16亿 USD0.79%US$41.50-0.80%
iShares Micro-Cap ETFIWC36.72万0.03%13.33亿 USD0.60%US$182.71-0.35%
Vanguard Health Care ETFVHT35.72万0.00%220亿 USD0.09%US$312.13-1.01%
Avantis U.S. Small Cap Equity ETFAVSC16.56万0.01%30.38亿 USD0.25%US$69.99+0.52%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOF/M Emerald Life Sciences Innovation ETFLFSCiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAvantis U.S. Small Cap Equity ETFAVSCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
